On December 23, 2025, Oncotelic Therapeutics, Inc. finalized a deal with 21 accredited investors to issue 32 units, each worth $25,000 with a 12% interest rate, convertible into 250,000 shares of its common stock at $0.10 per share and warrants for share purchase at $0.12.